Antwerp University Hospital (UZA) | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation	Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder	Recruiting	Phase 3	2026-06-22		NCT05696626
STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation	Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder	Active, not recruiting	Not applicable	2026-05-08		NCT04428944
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression	Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric neoplasm, gonadal disorder, head and neck cancer, head and neck squamous cell carcinoma, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, squamous cell carcinoma, stomach disorder, triple-negative breast carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder	Active, not recruiting	Phase 1 / Phase 2	2025-11-17		NCT04180371
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL	B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, diffuse large B-cell lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma	Recruiting	Phase 1 / Phase 2	2022-08-04		NCT04502394